Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company focused on diagnostic testing and diagnostic information services, and its news flow reflects its role across the healthcare ecosystem. The company regularly issues updates on its financial reporting schedule, including announcements about quarterly and full-year results and related conference calls, which are of interest to investors tracking DGX stock and performance trends.
News about Quest Diagnostics also covers participation in major healthcare and investor conferences. For example, the company has announced presentations at events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market developments. These appearances provide insight into how the company views its position in the diagnostic testing and information services market.
Quest Diagnostics’ news includes information on collaborations and joint ventures that expand access to laboratory services. Announcements have highlighted a laboratory services joint venture with Corewell Health in Michigan, as well as the ongoing role of Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics. Such items help readers understand how Quest Diagnostics partners with health systems to deliver regional laboratory services and hospital lab management solutions.
In addition, Quest Diagnostics reports on developments in specialized diagnostics through subsidiaries and collaborations. News has featured Haystack MRD, a minimal residual disease test developed by Haystack Oncology, a wholly owned subsidiary of Quest Diagnostics, including data presentations at scientific meetings and clinical research collaborations. Other coverage has described a strategic collaboration with Octave Bioscience to expand access to the Octave Multiple Sclerosis Disease Activity Test through Quest’s specimen-collection network.
Visitors to the DGX news page can review these types of updates to follow financial communications, strategic partnerships, scientific data presentations and corporate announcements that shape Quest Diagnostics’ activities in the medical laboratories sector.
Quest Diagnostics has awarded a grant to ConferMED, enhancing access to specialty care for underserved communities. The funding supports ConferMED's eConsult platform, connecting primary care providers in five U.S. regions with specialists. This initiative aims to address health inequities by providing virtual consultations at Federally Qualified Health Centers (FQHCs), impacting over 475,000 patients. The grant covers the full implementation cost and two years of services, improving chronic disease outcomes and reducing unnecessary hospital visits.
Quest Diagnostics announced partnerships aimed at facilitating safe participation in recreational activities post-COVID-19 pandemic. Key initiatives include acting as the sole on-site testing provider for the historic Boston Marathon, partnering with Carnival and Royal Caribbean for pre-cruise COVID-19 testing, and managing testing at the BNP Paribas Tennis Open. These efforts underscore Quest's commitment to health and safety during public events, helping to streamline testing procedures across various sectors.
Quest Diagnostics has launched multiple initiatives to support in-school COVID-19 testing, emphasizing the importance of safe classroom environments for children impacted by the pandemic. Key programs include the "Back to the Classroom" initiative, which focuses on K-12 testing solutions, partnerships with biotechnology firm Ginkgo Bioworks, and collaborations with various state health departments. Additionally, testing access is being expanded through partnerships with Battelle Memorial Institute to serve underserved populations. These efforts aim to facilitate safe educational settings for students, faculty, and staff.
Quest Diagnostics participated in the 8th annual I-HEAL Community Wellness Day in the Mississippi Delta, providing no-cost health screenings to approximately 80 attendees. The event, hosted by the Glenn Family Foundation, saw over 700 participants receive healthy food, flu shots, and health resources. Stacey Ingram from Quest emphasized the importance of the event in improving community health outcomes. The foundation has previously assisted over 7,000 food-insecure children and implemented health literacy programs, showcasing a robust commitment to community health improvement.
Quest Diagnostics (NYSE: DGX) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. Eastern Time. CEO Jim Davis and CFO Sam Samad will discuss the company's performance, strategy, and market trends. The live presentation will be webcast and available on their investor relations page. An archived version will be accessible within 24 hours and remain available until February 10, 2023.
Quest Diagnostics aims to empower individuals to enhance health outcomes through diagnostic insights.
Quest Diagnostics' latest Health Trends report reveals significant issues regarding drug misuse in the U.S. based on over 20 million drug tests conducted over the past decade. In 2021, 49% of individuals tested showed evidence of prescription drug misuse. Alarmingly, polysubstance use increased to 52%, up from 33% in 2012, while amphetamine use surged 5-fold, affecting 9.2% of those tested. The report emphasizes the ongoing risk of drug misuse across various age groups, particularly among younger adults, highlighting a pressing need for early intervention and preventive care.
Quest Diagnostics (NYSE: DGX) announced a strategic laboratory collaboration with Northern Light Health to acquire its outreach laboratory business and manage nine hospital laboratories in Maine. The agreement, selected after a competitive bid, is an all-cash transaction aimed at enhancing access to diagnostic services. The collaboration will leverage Quest's advanced testing capabilities, improving patient affordability and care in the region. Completion of the deal is expected in Q1 2023, although financial details remain undisclosed.
Getlabs and Sonora Quest Laboratories have announced a collaboration enhancing patient access to at-home lab testing. Through the integration of Getlabs' API into Sonora Quest's website, patients in Phoenix and Tucson can easily schedule in-home phlebotomy appointments. This initiative aims to improve patient convenience by eliminating logistical barriers to receiving vital health tests. The API is HIPAA compliant, ensuring secure handling of personal information. The collaboration reflects both companies' commitment to utilizing innovative technology for improved patient care.
Quest Diagnostics (DGX) has secured a group purchasing agreement with Premier Inc. (PINC) for its laboratory stewardship solutions. This collaboration enables Premier members to access Quest's Lab Stewardship Enterprise at special pricing, facilitating improved healthcare delivery. The platform offers data analytics for healthcare organizations, tracking trends and identifying cost-saving opportunities. Quest aims to enhance care quality and operational efficiency as health systems face post-pandemic challenges. This agreement marks a significant enhancement in accessibility for Quest's innovative healthcare solutions.
Quest Diagnostics (NYSE: DGX) has completed its acquisition of LabCare Plus, the outreach laboratory services business of Summa Health. This acquisition enables Quest to enhance access to its extensive test menu and health plan relationships in Northeastern Ohio. Patients and physicians will benefit from improved diagnostic services and lower out-of-pocket costs. Testing will be provided by Quest’s laboratories in Twinsburg, Ohio, and Pittsburgh, Pennsylvania, serving areas previously serviced by LabCare Plus.